Use of Bevacizumab in recurrent glioblastoma: A scoping review and evidence map

Glioblastoma (GBM) is the most malignant primary tumor in the brain, with poor prognosis and limited effective therapies. Although Bevacizumab (BEV) has shown promise in extending progressionfree survival (PFS) treating GBM, there is no evidence for its ability to prolong overall survival (OS)